Company plans to request End-of-Phase 2 meeting with FDA for AUD program
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.12
$0.14 (10 Analysts)
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune Inc is $19.00, about 533.3% above its August 11 closing price of $3.00
Q2 loss per share beats estimates
US biopharmaceutical firm's Q2 net loss per share beat analyst expectations
Company reported no revenue for Q2 2026
R&D expenses rose yr/yr due to ongoing ALD and MASH trials
Higher R&D and G&A costs drove results
Higher R&D spending - Co said increased R&D expenses were driven by ongoing ALD trial and startup costs for PERFORMA Phase 3 MASH trial, partially offset by lower costs after completing IMPACT Phase 2b trial
ALT•
